drugset / Trial / NCT07710885
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer
Timeline
- Start
- 2026-06-24
- Primary completion
- 2030-04-30
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Futibatinib | Small molecule | 20 mg | Oral |
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | 360 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |